Free Trial

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Citius Pharmaceuticals logo
$1.33 -0.07 (-5.00%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.33 0.00 (-0.30%)
As of 08/29/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Key Stats

Today's Range
$1.31
$1.57
50-Day Range
$1.03
$2.20
52-Week Range
$0.65
$15.25
Volume
2.36 million shs
Average Volume
341,734 shs
Market Capitalization
$22.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Consensus Rating
Moderate Buy

Company Overview

Citius Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

CTXR MarketRank™: 

Citius Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 488th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Citius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Citius Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($4.50) to $1.25 per share.

  • Price to Book Value per Share Ratio

    Citius Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.31% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Citius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Citius Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.31% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Citius Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    22 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.70% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 16.88% of the stock of Citius Pharmaceuticals is held by institutions.

  • Read more about Citius Pharmaceuticals' insider trading history.
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTXR Stock News Headlines

Citius Posts Wider Loss in Fiscal Q3
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.tc pixel
See More Headlines

CTXR Stock Analysis - Frequently Asked Questions

Citius Pharmaceuticals' stock was trading at $4.00 at the beginning of the year. Since then, CTXR stock has decreased by 66.8% and is now trading at $1.33.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its earnings results on Tuesday, August, 12th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04. The business had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.92 million.

Citius Pharmaceuticals's stock reverse split before market open on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Citius Pharmaceuticals include Geode Capital Management LLC (0.72%), NewEdge Advisors LLC (0.24%), XTX Topco Ltd (0.19%) and Arkadios Wealth Advisors (0.19%).
View institutional ownership trends
.

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/12/2025
Today
8/31/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTXR
CIK
1506251
Fax
N/A
Employees
20
Year Founded
2007

Price Target and Rating

High Price Target
$100.00
Low Price Target
$6.00
Potential Upside/Downside
+3,885.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.14 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.03%
Return on Assets
-33.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
17,010,000
Free Float
15,192,000
Market Cap
$22.62 million
Optionable
Optionable
Beta
1.19

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CTXR) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners